Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Urogynecology Journal

06.12.2018 | Clinical Opinion

IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity

verfasst von: S. Abbas Shobeiri, M. H. Kerkhof, Vatche A. Minassian, Tony Bazi, on behalf of the IUGA Research and Development Committee

Erschienen in: International Urogynecology Journal

Einloggen, um Zugang zu erhalten

Abstract

This committee opinion reviews the laser-based vaginal devices for treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The United States Food and Drug Administration has issued a warning for unsubstantiated advertising and use of energy-based devices. Well-designed case–control studies are required to further investigate the potential benefits, harm, and efficacy of laser therapy in the treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The therapeutic advantages of nonsurgical laser-based devices in urogynecology can only be recommended after robust clinical trials have demonstrated their long-term complication profile, safety, and efficacy.
Literatur
1.
Salvatore S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845–9.CrossRefPubMed
2.
FDA. FDA warns against use of energy-based devices to perform vaginal 'rejuvenation' or vaginal cosmetic procedures: FDA Safety Communication. 2018. [2018 August 1].
3.
Practice, C.o.G. ACOG Committee opinion no. 378: vaginal rejuvenation and cosmetic vaginal procedures. Obstet Gynecol. 2007;110(3):737.CrossRef
4.
5.
Nappi RE, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE survey. Climecteric. 2016;19:188–97.CrossRef
6.
Portman DJ, ML G. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's sexual health and the North American Menopause Society. Menopause. 2014;21:1063–8.CrossRefPubMed
7.
Pardo JS, Solà VD, Ricci PA. Colpoperineoplasty in women with a sensation of a wide vagina. Acta Obstet Gynecol Scand. 2006;85:1125–7.CrossRefPubMed
8.
Moore RD, Miklos JR, O C. Evaluation of sexual function outcomes in women undergoing vaginal rejuvenation/vaginoplasty procedures for symptoms of vaginal laxity/decreased vaginal sensation utilizing validated sexual function questionnaire (PISQ-12). Surg Technol Int. 2014;24:253–60.PubMed
9.
Haylen BT, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). Neurourol Urodyn. 2016;35(2):137–68.CrossRefPubMed
10.
Pauls RN, Fellner AN, GW D. Vaginal laxity: a poorly understood quality of life problem; a survey of physician members of the International Urogynecological Association (IUGA). Int Urogynecol J. 2012;23:1435–48.CrossRefPubMed
11.
Millheiser L, Kingsberg S, Pauls R. A cross-sectional survey to assess the prevalence and symptoms associated with laxity of the vaginal introitus [abstract 206]. In: ICS Annual Meeting. Toronto, Ontario, Canada; 2010.
12.
Roos AM, Sultan AH, R T. Sexual problems in the gynecology clinic: are we making a mountain out of a molehill? Int Urogynecol J. 2012;23:145–52.CrossRefPubMed
13.
MacLennan AH, Taylor AW, Wilson DH. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG. 2000;107:1460–70.CrossRefPubMed
14.
15.
Tadir Y, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49:137–59.CrossRefPubMedPubMedCentral
16.
Lang P, Karram M. Lasers for pelvic floor dysfunctions: is there evidence? Curr Opin Obstet Gynecol. 2017;29(5):354–8.CrossRefPubMed
17.
Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017;28:681–5.CrossRefPubMed
18.
Isaza PG, Jaguszewska K, Cardona JL, Lukaszuk M. Long-term effect of thermoablative fractional CO2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. Int Urogynecol J. 2018;29(2):211–5.
19.
Lapii GA, Yakovleva AY, Neimark AI. Structural reorganization of the vaginal mucosa in stress urinary incontinence under conditions of Er:YAG laser treatment. Bull Exp Biol Med. 2017;162(4):510–4.CrossRefPubMed
20.
Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008;58(5):719–37.CrossRefPubMed
21.
Pitsouni E, et al. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas. 2016;94:131–6.CrossRefPubMed
22.
Siliquini GP, et al. Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. Climacteric. 2017;20(4):379–84.CrossRefPubMed
23.
Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016;23(10):1102–7.CrossRefPubMed
24.
Sokol ER, Karram MM. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause. 2017;24(7):810–4.CrossRefPubMed
25.
Gaspar A, et al. Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49(2):160–8.CrossRefPubMed
26.
Behnia-Willison F, et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017;213:39–44.CrossRefPubMed
27.
Pieralli A, et al. Erratum to: Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms. Arch Gynecol Obstet. 2017;296(6):1237.CrossRefPubMed
28.
Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(1):21–8.
29.
Gambacciani M, et al. Rationale and design for the vaginal erbium laser academy study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18(Suppl 1):43–8.CrossRefPubMed
30.
Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric. 2015;18(5):757–63.CrossRefPubMedPubMedCentral
31.
32.
Gaspar A, Brandi H. Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency). Lasers Med Sci. 2017;32(3):685–91.CrossRefPubMed
33.
Fistonic N, et al. Minimally invasive, non-ablative Er:YAG laser treatment of stress urinary incontinence in women--a pilot study. Lasers Med Sci. 2016;31(4):635–43.CrossRefPubMedPubMedCentral
34.
Pardo JI, Sola VR, Morales AA. Treatment of female stress urinary incontinence with erbium-YAG laser in non-ablative mode. Eur J Obstet Gynecol Reprod Biol. 2016;204:1–4.CrossRefPubMed
35.
Fistonić N, et al. First assessment of short-term efficacy of Er: YAG laser treatment on stress urinary incontinence in women: prospective cohort study. Climacteric. 2015;18(sup1):37–42.CrossRefPubMed
36.
37.
Fistonic I, et al. Laser treatment of early stages of stress urinary incontinence significantly improves sexual life. In: Annual Conference of European Society for Sexual Medicine. 2012.
38.
Khalafalla M, et al. Minimal invasive laser treatment for female stress urinary incontinence. Obstet Gynecol Int J. 2015;2(2):00035.CrossRef
39.
Tien YW, et al. Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. Int Urogynecol J. 2017;28(3):469–76.CrossRefPubMed
40.
Pergialiotis V, et al. A systematic review on vaginal laser therapy for treating stress urinary incontinence: do we have enough evidence? Int Urogynecol J. 2017.
41.
FDA. Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for vaginal rejuvenation. 2018. (cited 2018 August 1).
Metadaten
Titel
IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity
verfasst von
S. Abbas Shobeiri
M. H. Kerkhof
Vatche A. Minassian
Tony Bazi
on behalf of the IUGA Research and Development Committee
Publikationsdatum
06.12.2018
Verlag
Springer International Publishing
Erschienen in
International Urogynecology Journal
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-018-3830-0

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika
weitere anzeigen

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen